Piromelatine

Drug Profile

Piromelatine

Alternative Names: Neu-P11

Latest Information Update: 04 Oct 2016

Price : $50

At a glance

  • Originator Neurim Pharmaceuticals
  • Class Sleep disorder therapies
  • Mechanism of Action Melatonin receptor agonists; Serotonin 1A receptor agonists; Serotonin 1D receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease; Insomnia; Ocular hypertension
  • No development reported Metabolic syndrome

Most Recent Events

  • 04 Oct 2016 Phase-II clinical trials in Ocular hypertension in Spain (PO) (EudraCT2016-002281-31)
  • 28 Sep 2016 Neurim Pharmaceuticals reinitiates enrolment in a phase II ReCOGNITION trial for Alzheimer's Disease in USA (PO)
  • 07 Apr 2016 Neurim Pharmaceuticals suspends patient recruitment in the phase II ReCOGNITION trial for Alzheimer's disease in USA (PO) (NCT02615002)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top